ArticleJournal for immunotherapy of cancer2024

Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.

Noboru Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.